Welcome!

News Feed Item

Bone Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

Bone Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Bone Cancer Global Clinical Trials Review, H1, 2014" provides data on the Bone Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Bone Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Bone Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Bone Cancer 25
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Bone Cancer Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Bone Cancer 37
Jan 03, 2014: Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial of ILC for Pediatric Bone Cancer 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
F. Hoffmann-La Roche Ltd. 46
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 46
Amgen Inc. 48
Clinical Trial Overview of Amgen Inc. 48
Bayer AG 50
Clinical Trial Overview of Bayer AG 50
Takeda Pharmaceutical Company Limited 52
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 52
Merck & Co., Inc. 53
Clinical Trial Overview of Merck & Co., Inc. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
AstraZeneca PLC 55
Clinical Trial Overview of AstraZeneca PLC 55
Eli Lilly and Company 56
Clinical Trial Overview of Eli Lilly and Company 56
Algeta ASA 57
Clinical Trial Overview of Algeta ASA 57
Clinical Trial Overview of Top Institutes / Government 58
National Cancer Institute 58
Clinical Trial Overview of National Cancer Institute 58
Children's Oncology Group 67
Clinical Trial Overview of Children's Oncology Group 67
The University of Texas M. D. Anderson Cancer Center 70
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 70
Memorial Sloan Kettering Cancer Center 72
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 72
Massachusetts General Hospital 74
Clinical Trial Overview of Massachusetts General Hospital 74
European Organization for Research and Treatment of Cancer 75
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 75
Southwest Oncology Group 76
Clinical Trial Overview of Southwest Oncology Group 76
University Health Network 77
Clinical Trial Overview of University Health Network 77
Stanford University 78
Clinical Trial Overview of Stanford University 78
Five Key Clinical Profiles 79
Appendix 180
Abbreviations 180
Definitions 180
Research Methodology 181
Secondary Research 181
About GlobalData 182
Contact Us 182
Disclaimer 182
Source 183

List of Tables

Bone Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Bone Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Bone Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 46
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 48
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 50
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 52
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 53
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 55
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 56
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2014* 57
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 58
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 67
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 70
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 72
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 74
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 75
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 76
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 77
Bone Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 78

List of Figures

Bone Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Bone Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Bone Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Bone Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Bone Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Bone Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Bone Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Bone Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Bone Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Bone Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Bone Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Bone Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Bone Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Bone Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Bone Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Bone Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Bone Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Bone Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Bone Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Bone Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 181

Read the full report:
Bone Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.